Biotech is always an exciting sector for market players to invest in. The space is full of high risk but also high reward for investors who can stomach the volatility.In just 2009 alone, we have seen some amazing moves in biotech stocks, including Dendreon ( DNDN, Vanda Pharmaceuticals ( VNDA - Get Report) and Cell Therapeutics ( CTIC - Get Report). In the case of Dendreon and Vanda, both companies received favorable FDA rulings that sent their stocks skyrocketing. A drug approval for an early stage biotech stock is a very big development for these companies. Often these firms are struggling to stay in business as research and developments costs eat through their cash positions. Unfortunately, the only way that biotech companies have a chance at coming to market with a successful drug is by spending money on R&D. A good way to gauge how well a biotech company is doing is to simply follow the FDA trials for its key drugs. If you follow the trials, you can see if any potential drug is advancing or showing positive results. Of course, these trials make for great catalysts for the stocks, especially when there is bullish news. A great place to find information about upcoming clinical trials is TheStreet.com's Adam Feuerstein's Biotech Calendar, which lists companies coming up on trials for phase II and phase III studies. Combine that key information with an unemotional view of a potential company's stock chart, and you might be able to spot some big opportunities in the biotech sector. Considering that there are a number of companies poised to report key clinical results, it might be well worth the time to evaluate their charts. Let's take a look at the charts of a few biotech stocks that could be setting up to make big moves. To read more, visit Stockpickr.com.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Investing
Does the 4% Rule for Retirement Savings Really Work?
Are you considering the 4% rule for your retirement savings plan? Be sure you understand the risks involved, watch the video for more.
Jim Cramer Unveils His 5 Rules for Trading Stocks During Earnings Season
Jim tells members of his Action Alerts PLUS club for investors what to look for when earnings reports come in.
Everything Cannabis Investors Need to Know About This Year's 420 'Holiday'
Sales for Pot Holiday 420 will get rolling early this year. Any cannabis investor should pay attention.
Freeport-McMoRan Is Switching Into Bull Market Mode
After a rough 2018, Freeport-McMoRan is a 'buy the dips' stock.
Comcast Regains Its Swagger in a Brutal New Era of Streaming
Customers have a love/hate relationship with the cable TV industry because of continuously rising prices and poor customer service. The flip side is that cable TV, as a product, works, and Comcast can exploit that like no other.